Accordingly, activation of the CB1 receptor could be proven to contribute to the antiproliferative action of 2-AG on nerve growth factor-stimulated breast cancer cells (Melck et al., 2000) and to its proapoptotic action on prostate cancer cells (Orellana-Serradell et al., 2015) when using 2-AG concentrations in the range of 0.5–5 μM and 5 μM, respectively. The gene discussed is NGF; the disease is prostate cancer.